Every 424B that Relmada Therapeutics, Inc. (RLMD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow RLMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RLMD filings page.
Relmada Therapeutics, Inc. registers 33,685,096 shares of common stock for resale by selling stockholders pursuant to a registration statement covering (i) 29,474,569 shares issued in a Private Placement and (ii) 4,210,527 shares issuable upon exercise of pre-funded warrants.
The prospectus states the company will receive no proceeds from resales under this registration; proceeds from any exercise of the Pre-Funded Warrants would be received by the company. Shares outstanding were 104,888,233 as of March 20, 2026. The resale may occur through a variety of methods at varying prices, and the Registration Rights Agreement requires the company to use commercially reasonable efforts to cause the registration statement to become effective within the agreed timeframes.
Relmada Therapeutics, Inc. has updated its at-the-market stock sales program to offer up to $100,000,000 of common stock through Jefferies LLC as sales agent under an existing Open Market Sale Agreement.
The company states it has not previously sold any shares under this program and is amending the prior prospectus materials to reflect the higher aggregate amount. Relmada’s common stock trades on the Nasdaq Global Select Market under the symbol RLMD, and the last reported sale price was $3.91 per share on January 29, 2026. The company also notes it is no longer subject to the Form S-3 General Instruction I.B.6 limitations because the aggregate market value of its non-affiliate holdings was at least $75.0 million as of January 28, 2026.
Relmada Therapeutics (RLMD) launched a primary offering of 40,142,000 shares of common stock at $2.20 per share and pre-funded warrants for 5,315,000 shares, together with 5,315,000 shares issuable upon exercise of those pre-funded warrants. Gross proceeds are $100,000,085, with underwriting discounts of $6,000,324 and proceeds before expenses of $93,999,761; the company estimates net proceeds of approximately $93.7 million.
Relmada plans to use the funds for working capital and general corporate purposes, including clinical studies and development of product candidates. Pre-funded warrants are immediately exercisable at $0.001 per share, with an ownership cap of 9.99% (or 4.99% at the holder’s election). Certain officers indicated interest in up to about $2.6 million of shares at the offering price, which is non-binding. Shares outstanding would be 73,333,622 immediately after the offering, assuming no exercise of pre-funded warrants. As of October 24, 2025, shares outstanding were 33,191,622.